Spots Global Cancer Trial Database for Clinical Trial of Comparative Study of GB221 Pharmacokinetics
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Clinical Trial of Comparative Study of GB221 Pharmacokinetics
Official Title: A Randomized, Double-blind, Parallel-group, Comparative Phase I Study to Evaluate the Safety and Pharmacokinetics of Single Intravenous (IV) Administration of GB221 Versus Herceptin® (Trastuzumab)
Study ID: NCT04175171
Conditions
Study Description
Brief Summary: The primary objective is to assess the safety of a single dose of GB221 compared to Herceptin® when administered as a single IV injection at a dose of 8 mg/kg. The secondary objective of the study is to assess the pharmacokinetics of GB221 compared to Herceptin®.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: MALE
Healthy Volunteers: Yes
Locations
Linear Clinical Research Limited, Nedlands, Western Australia, Australia
Contact Details
Name: Andrewn Redfer, PhD; MBBS
Affiliation: Linear Clinical Research Limited
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
